Keywords
IV iron
Phosphorus
Parathormone
Chronic kidney disease
How to Cite
Abstract
Context: Ferric carboxymaltose (FCM) is a widely used therapy in chronic kidney disease (CKD). With its increasing use, hypophosphatemia -an unexpected side effect- has drawn growing attention. While the risk of hypophosphatemia decreases as the chronic kidney disease stage progresses, the impact of ferric carboxymaltose on parathormone levels and how this risk evolves with repeated doses remain less known.
Objective: In our study, we planned to evaluate the relationship of ferric carboxymaltose with phosphorus and parathormone in the long term in patients with stage 2-5 non-dialysis chronic kidney disease.
Method: All chronic kidney disease patients who received ferric carboxymaltose treatment between January 2022 and March 2023 were screened. Basal phosphorus values of the patients and phosphorus values in the first and second controls were recorded as F0, F1, and F2, respectively. Parathormone values were recorded in the first control after the second dose of ferric carboxymaltose.
Results: A total of 49 patients met the criteria, of whom 31 patients were female (63%). Thirty-two patients (65%) received a single dose of treatment. The mean age was 67±12, with a mean dose of 969±483 mg. The mean GFR was 36±14.
When comparing single- and double-dose groups, no significant differences were observed in age, gender distribution, chronic kidney disease stage, baseline phosphorus levels (F0), or the time to the first follow-up.
Between F0 and F1, there was a significant decrease of 0.2 and 0.3 mg/dL in phosphorus levels in both groups, respectively. No patient developed clinically apparent hypophosphatemia. No significant difference was found when the F0-F2 and F1-F2 values were compared in patients who received two treatment doses. Parathormone levels increased slightly in the same patient group, although not statistically significant.
Conclusion: While ferric carboxymaltose causes a mild phosphorus reduction at high doses in chronic kidney disease patients not receiving dialysis treatment, this effect is not permanent. Prospective studies with sufficient patients are needed to elucidate the impact of fluctuations in phosphorus levels caused by this treatment on parathormone and chronic kidney disease -related bone disease.
References
Süleymanlar G, Uta? C, Arinsoy T, Ate? K, Altun B, Riza-Altiparmak M, et al. A population-based survey of Chronic REnal Disease In Turkey-the CREDIT study. Nephrol Dial Transplant. 2011;26(6):1862-1871. https://doi.org/10.1093/ndt/gfq656
Portoles J, Martin L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne). 2021:8:642296. https://doi.org/10.3389/fmed.2021.642296
Gutierrez OM. Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease. Kidney Int Rep. 2021;6(9):2261-2269. https://doi.org/10.1016/j.ekir.2021.05.020
Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69:739-756. https://doi.org/10.2165/00003495-200969060-00007
Khan MS, Usman MS, von Haehling S, Doehner W, Stewart Coats AJ. Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis. ESC Heart Fail. 2020;7(6):3392-3400. https://doi.org/10.1002/ehf2.13146
García García E, Romero González MÁ, Mendoza Mendoza S, Gómez Gómez A. Evaluación de la administración de carboximaltosa férrica intravenosa en la consulta de enfermedad renal crónica avanzada, para el control de la anemia. Enferm Nefrol. 2016;19(2):113-117. https://doi.org/10.4321/S2254-28842016000200002
Basha A, Ibrahim MIM, Hamad A, Chandra P, Omar NE, Abdullah MAJ, et al. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia. PLoS One. 2021;16(8):e0255104. https://doi.org/10.1371/journal.pone.0255104
Okada M, Imamura K, Iida M, Fuchigami T, Omae T. Hypophosphatemia induced by intravenous administration of Saccharated iron oxide. Klin Wochenschr. 1983;61:99-102. https://doi.org/10.1007/BF01496662
Rognoni C, Venturini S, Meregaglia M, Marmifero M, Tarricone R. Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. Clin Drug Investig. 2016;36:177-194. https://doi.org/10.1007/s40261-015-0361-z
Boots JMM, Quax RAM. High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment. Drug Saf. 2022;45:1019-1036. https://doi.org/10.1007/s40264-022-01216-w
Kassianides X, Bhandari S. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drugs Context. 2021;10:2020-11-3. https://doi.org/10.7573/dic.2020-11-3
Glaspy JA, Wolf M, Strauss WE. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Adv Ther. 2021;38:3531-3549. https://doi.org/10.1007/s12325-021-01770-2
Merino JL, Bueno B, Campos MA, Amézquita Y. Carboximaltosa férrica intravenosa en el tratamiento de la anemia en enfermedad renal crónica. Rev Clin Esp. 2014;214(5):282-283. https://doi.org/10.1016/j.rce.2014.01.010
Prats M, Font R, Garcia C, Cabre C, Jariod M, Vea AM. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study. BMC Nephrol. 2013;14:167. https://doi.org/10.1186/1471-2369-14-167
Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. Jama. 2020;323(5):432-443. https://doi.org/10.1001/jama.2019.22450
Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256-2273. https://doi.org/10.1111/bcp.14643
Rosano GM, Kalantar-Zadeh K, Jankowska EA. Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials. ESC Heart Fail. 2023;10(2):1294-1304. https://doi.org/10.1002/ehf2.14286
?umnu A, Dal AE. Hypophoshatemia Incidence in Patients with Chronic Kidney Disease Treated with Intravenous Ferric Carboxymaltose and Factors Related to Hypophosphatemia. Med Bull Haseki. 2020;58(4):338-343. https://doi.org/10.4274/haseki.galenos.2020.5947
Portoles-Perez J, Dura-Gurpide B, Merino-Rivas JL, Martín-Rodrigiguez L, Hevia-Ojanguren C, Burguera-Vion V, et al. Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study. Clin Kidney J. 2021;14(1):174-180. https://doi.org/10.1093/ckj/sfz153
Merino JL, García E, Castrillo S, Mendoza S, Sánchez V, Bueno P, et al. Optimizing Control of Anemia with Ferric Carboxymaltose Administration in Peritoneal Dialysis. J Clin Nephrol Ren Care. 2019;5:044. https://doi.org/10.23937/2572-3286.1510044
Lacquaniti A, Pasqualetti P, Tocco TCD, Campo S, Rovito S, Bucca M, et al.Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. Kidney Res Clin Pract. 2020;39(3):334-343. https://doi.org/10.23876/j.krcp.20.015
Frazier R, Hodakowski A, Cai X, Lee J, Zakarija A, Stein B, et al. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency. Bone. 2020;141:115559. https://doi.org/10.1016/j.bone.2020.115559
Zoller H, Wolf M, Blumenstein I, Primas C, Lindgren S, Thomsen LL, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023;72(4):644-653. https://doi.org/10.1136/gutjnl-2022-327897
Vilaca T, Velmurugan N, Smith C, Abrahamsen B, Eastell R. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. J Bone Miner Res. 2022;37(6):1188-1199. https://doi.org/10.1002/jbmr.4558
Panzer M, Meindl E, Schaefer B, Wagner S, Glodny B, Mayer G, et al. Intravenous iron-induced hypophosphatemia and kidney stone disease. Bone Rep. 2024;21:101759. https://doi.org/10.1016/j.bonr.2024.101759
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.